BRCA2 and neoplasm: Next, we tested whether expression of BRCA2-001/Short affected overall survival across 67 BRCA1/2 mutation carriers (from discovery and validation cohorts) for whom we had survival data and RNA sequenced from at least one tumor (Supplementary Data 15).